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In the past decade, numerous studies have made connections between sequence variants in human genomes and
predisposition to complex diseases. However, most of these variants lie outside of the charted regions of the
human genome whose function we understand; that is, the sequences that encode proteins. Consequently, the
general concept of a mechanism that translates these variants into predisposition to diseases has been lacking,
potentially calling into question the validity of these studies. Here we make a connection between the growing
class of apparently functional RNAs that do not encode proteins and whose function we do not yet understand
(the so-called ‘dark matter’ RNAs) and the disease-associated variants. We review advances made in a different
genomic mapping effort – unbiased profiling of all RNA transcribed from the human genome – and provide
arguments that the disease-associated variants exert their effects via perturbation of regulatory properties of
non-coding RNAs existing in mammalian cells.
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Connecting variations in DNA sequence with a biological
or medical phenotype has long served to map functional
elements of a genome. The recent genomics revolution
has facilitated the identification of such variants on a
massive scale, ushering in the era of genome-wide associ-
ation studies (GWAS). Since the first pioneering report in
2005 [1], hundreds of such analyses have identified
thousands of changes in DNA sequence (primarily single
nucleotide polymorphisms (SNPs)) associated with a large
number of complex diseases (cancers, heart disease, brain
disorders, obesity, and many others; [2,3]. However, most
of these variants have accumulated in unannotated, non-
coding regions of the genome, whose functions continue
to pose an enigma (Figure 1). Therefore, much of the
wealth of GWAS information remains unrealized, with
the mechanisms of action of the underlying genomic
regions unknown, despite their widespread associations
with disease.* Correspondence: philipp@stlaurentinstitute.org
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2014Pervasive transcription: the answer to function behind
the non-coding GWAS variants?
Only 2 to 3% of human DNA (genome) encodes proteins,
the building blocks of life whose function we understand
fairly well. The remaining 97 to 98% represent non-coding
sequences, which were long considered ‘junk DNA’ be-
cause they did not fit the protein-centric view that domi-
nated biology for decades. The goal of connecting DNA
sequence variants to this protein-coding sliver of the hu-
man genome has shaped their interpretation, yet over 90%
of GWAS hits lie in the non-coding parts of the genome
(Figure 1; see Additional file 2: Supplementary Tables 1–3).
(Table 1). Three possible explanations exist for the large
preponderance of non-coding GWAS hits. They could
arise from methodological errors such as imprecise mea-
surements of phenotypes [4], differences in population
structures [5] or DNA quality issues [6,7] between cases
and controls. Second, they could affect distal regulatory
regions of known (mostly protein-coding) genes. Third,
they could represent novel genes or transcripts. However,
as the number of GWAS increase, support for the first
two arguments continues to weaken. The sheer number of
non-coding GWAS hits, their continued accumulation
as statistical power has improved, and their consistenttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Discovery of genome-wide association studies (GWAS) variants in different genomic elements and disease types. GWAS
variants were assigned to a disease type (y axis) or non-disease traits. For each disease type, the P-value (x axis) for a skew towards a particular
genomic category (x xis) was calculated (see Additional file 1: Supplementary Text). Numbers of unique GWAS variants for each of the genomic
categories are shown as the purple bars; the corresponding numbers for each of the disease types are shown in parenthesis. Only disease types
with >100 GWAS variants are shown. CDS, coding DNA sequence (coding regions of known genes); UTR, untranslated region (non-coding regions
of known genes; promoter and intronic regions are those of known genes). See Additional file 1: Supplementary Text for details of the analysis.
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(Figure 1), argues against a widespread pattern of errors.
Although errors must exist, they are unlikely to represent
such a large proportion of GWAS events. Similarly, distal
enhancers and regulatory regions will eventually explain
some fraction of non-coding GWAS hits. However, these
variants must interrupt fairly small sites of transcription
factor binding and chromatin signaling within the regu-
latory regions, which represent a small minority of the
genome. For example, Khurana et al. [8] reported that
conserved transcription factor binding motifs and DNAse
I hypersensitive regions make up only 0.4% of the genome.
As expected, only 88 out of approximately 12,000 vari-
ants in the National Human Genome Research Institute
GWAS catalog currently map to these regions. Therefore,
the third explanation, that non-coding SNPs affect novel
genes or transcripts, has begun to take center stage. In
effect, the broad and continued accumulation of GWAS
data, with the same pattern of distribution in non-coding
regions, highlights the importance of pervasive transcrip-
tion and dark matter RNA.In 2002, the first report of pervasive transcription [9]
subsequently triggered a series of genome-mapping en-
deavors that have discovered large numbers of dark
matter RNAs transcribed from much of the non-coding
space of the human genome [10-12]. Although an object
of considerable debate over the last decade [13], an in-
creasing number of independent observations in different
species [14-19] have confirmed these results by continually
increasing the annotation of the dark matter transcriptome.
Presently, little doubt remains that the human genome
produces large amounts of RNA whose function we still
do not understand [10-12]. In fact, non-coding (nc)RNA
represents at least 75% of the human genome [20], and
its relative mass outweighs that of protein-coding
mRNA [21].
These large and well-validated datasets now provide a
strong basis for an in-depth look at ncRNA as a possible
answer to the mystery of the many GWAS hits that do
not fall neatly into protein-coding regions of the human
genome. The non-coding disease-associated polymor-
phisms from the GWAS studies may have uncovered a
Table 1 Glossary of technical terms
Term Meaning
Chromatin signaling A system of regulation of gene activity in a cell that works by affecting the
immediate surroundings of DNA, for example, by modifying various proteins that
coat DNA inside the nucleus. Depending on the exact nature of the modification, DNA
becomes either more or less accessible to cellular machinery that activates genes
Enhancer A sequence of DNA that can regulate a target gene or genes over long distances
DNAse I hypersensitivity region A region of DNA identified in an assay where chromatin is digested with DNAse I,
an enzyme that degrades DNA. More accessible regions of chromatin, typically
containing regulatory elements such as promoters and enhancers, are more
susceptible to DNAse digestion and thus are enriched in DNAse I hypersensitivity
regions
Gene Ontology (GO) term GO is a an international initiative aimed at assigning controlled vocabulary,
consisting of terms such as ‘regulation of apoptosis’ that define the functional
property of each gene. This vocabulary is often very useful in understanding
the biological meaning of a genomics experiment. For example, a list of genes
activated during a disease would have a list of specific terms associated with
each gene. Enrichment of specific terms in the list would suggest general
cellular functions in which these genes participatem and give clues to the
molecular functions underlying the disease
H1 embryonic stem cells A line of human embryonic stem cells maintained in culture
H3K27 trimethylation A certain type of chemical modification of a protein that binds DNA.
Important for reversible deactivation oftargeted portions of the genome
Intron Part of an RNA molecule that is included immediately after transcription and
removed during maturation of that molecule
Intronic RNA RNA encoded by a DNA sequence that also encodes an intron of another transcript
lincRNA-p21 A non-coding RNA activated upon DNA damage and in various tumor cell lines
MYC gene A gene encoding an important regulator controlling activity of many genes. This
gene has been associated with many cancers
Normal human epidermal keratinocytes (NHEK) A line of primary keratinocytes maintained in culture
Non-coding RNA RNA that is not used as a template for protein synthesis
Pervasive transcription Massive transcription from unannotated regions of the genome
PolyA+ RNA A molecule of RNA containing a long stretch of adenosine residues at the end
PRC2 chromatin signaling complex A complex composed of multiple protein molecules that reversibly modifies chromatin
and silences target genes
Promoter A sequence of DNA that is located immediately adjacent to a target gene and
regulates its activity
Pseudogene A copy of a gene, presumed to be non-functional, although a number of recent
examples describe both non-coding functions and occasionally coding functions
for some of these loci
Regulation in trans Regulation via interaction with molecules encoded by distal regions of the genome
RNA Pol II A complex composed of multiple protein molecules responsible for synthesis of RNA,
which is used as template for protein synthesis
Transcript A molecule of RNA produced by transcription, that is, copying of RNA from the DNA
template
Transcription factor A protein that regulates expression of genes by binding to their promoters and/or
enhancers
Transcription factor motif A short DNA sequence recognized by a transcription factor or group of transcription
factors, typically found in promoters and enhancers
Transcriptome A collection of all the RNA molecules (transcripts) in a cell or a tissue
Transcriptomics Study of the transcriptome
Xenopus oocytes Oocytes from frogs of genus Xenopus, an important model system for study of
developmental biology, cell biology, molecular biology, toxicology, and neuroscience
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scripts and their network of interactions in the cell.
Below we describe the evidence supporting this view,
and explain how this perspective can solve a number of
outstanding questions.
Undiscovered transcripts may underlie non-coding
GWAS variants
As discussed by Mudge et al. [12] in their excellent review
on functional transcriptomics, we have only begun to an-
notate the full complexity of RNAs encoded by the human
genome. First, the database of complete, full-length
cDNAs – the basis for gene annotations – still has sur-
prisingly shallow coverage [10]. In fact, for many gene
loci, the database contains only a single complete cDNA.
This implies that most protein-coding genes, even
well-characterized ones, have yet undiscovered exons
that would require highly sensitive in-depth profiling
methods to reveal [22,23]. With much less coverage
than coding genes, the annotation situation for
ncRNAs remains far more incomplete. The main rea-
sons for this include the over-reliance on methods de-
signed for protein-coding mRNAs, such as the use of
polyA+ RNA for transcriptome profiling, the analytical
focus on spliced RNAs, and the avoidance of intronic
RNAs. The vast majority of RNA sequencing (RNAseq)
experiments so far have profiled the polyA+ RNA fraction.
Although this is informative for mRNAs, it leads to loss of
significant complexity of ncRNAs [21], and a bias against
the discovery of their unspliced versions. As a conse-
quence, spliced versions of ncRNAs dominate the current
annotated lists, which has resulted in an underestimate of
their genomic coverage. It is very possible that, unlike
protein-coding mRNAs, the longer, unspliced versions of
the ncRNAs represent the functional forms. The abun-
dance of ncRNAs in the nucleus compared to the cytosol
[18] makes this a likely scenario.
Partly to bring order to this complexity, annotation
efforts have classified ncRNAs by their physical charac-
teristics. Typically, they are defined based on length
(short, long, or very long), location relative to known
genomic features (introns, genes, promoters, enhancers,
or intergenic space), and overlap of known genes (sense or
antisense) [12]. Of greatest importance to GWAS,long
ncRNAs (lncRNAs) include all the classes of ncRNAs
greater than 200 nucleotides in length, such as long
intergenic ncRNAs (lincRNAs) [24], very long intergenic
ncRNAs (vlincRNAs; (>40 kb in length, see below), nat-
ural antisense RNAs, and intronic RNAs [19,25-27].
Genomic annotation efforts typically focus on intergenic
regions as the logical place to look for novel genes and
transcripts, following the general notion that introns of
known genes probably represent mere pre-mRNAs.
However, this simple assumption has failed in the lightof recent RNAseq datasets, as we have shown in a mouse
inflammation time-course experiment [28]. In fact, thou-
sands of mouse introns can harbor functional ncRNAs
that behave separately from their exonic counterparts
[28], resonating with discoveries of independent intronic
RNAs in other systems such as Xenopus oocytes [29].
These observations support visionary ideas originally con-
ceived by John Mattick almost 2 decades ago [30].
Strikingly, discovery of GWAS variants seem to favor
different genomic elements depending on disease type
(Figure 1). Only two disease types showed a preference
for discovery of GWAS variants in coding regions of
known genes (CDSs): metabolic diseases and anatom-
ical diseases. By contrast, diseases affecting mental health
favored annotated lncRNAs (lincRNAs and vlincRNAs),
while cellular proliferation diseases favored introns
(Figure 1). The even distribution in the non-disease
trait category (which includes a large number of different
phenotypes) provides a perspective for the contrasting re-
sults in the disease categories. Although understanding
these observations will require additional research, we
hope they raise the question of why variants in different
diseases favor different categories of genomic elements.
For example, it is tempting to speculate that the prefer-
ence for promoters in anatomical diseases relates to the
importance of tight control of gene expression during
development.
As alluded to above, most of the existing lists of
lncRNAs come from profiling of polyA+ RNA. By con-
trast, sequencing of total RNA from normal and tumor
tissues recently uncovered vlincRNAs), a novel class of
lncRNAs that showed statistically significant associations
with GWAS variants [31]. Thousands of these vlincsRNAs
span at least 10% of the human genome, and probably
span much more, once additional tissues are profiled.
These RNAs range from 40 kb up to around 1 MB
in length, and are controlled by typical RNA Pol II
promoters. Interestingly, an intriguing subset of these
RNAs – those controlled by promoters within endogen-
ous retroviral elements – characterizes cancerous and
pluripotent states.
Figure 2 illustrates a cancer-associated region, for
which GWAS has highlighted the potential importance
of vlincRNAs. This 8q24 region upstream of the MYC
gene shows a high level of transcription in two normal
human cell lines: H1 embryonic stem cells and normal
human epidermal keratinocytes (NHEK), which are primary
keratinocytes [20]. vlincRNA transcription occurs on both
strands, probably in part from normal RNA Pol II pro-
moters [32] (Figure 2, red arrows). In total, vlincRNAs
[31] span 727 kb of that 1.2 MB region and overlap a
number of GWAS SNPs. Lower level transcription over-
laps additional GWAS SNPs, suggesting the presence of
unannotated transcripts in those regions, consistent with
Figure 2 A genomic view of the 8q24 region upstream of the MYC gene. For details, see text.
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associated ncRNAs in this region, the 2,613 bp-long
CCAT1 [33] and the 340 bp-long CCAT2 [34], represent
only a tiny fraction of its transcriptional complexity. Quite
possibly, they encompass only segments of much longer
transcripts. In fact, the current profile of transcription
leaves us with an attractive possibility that a cluster of
GWAS SNPs spanning around 500 kb works via its pres-
ence in a small set of very long ncRNAs. Obviously, all
this shows that we have only begun the exploration of
RNAs made in this important region, and by association,
many regions throughout the genome, where unexplained
non-coding GWAS hits occur. Widespread presence of
such very long RNAs suggests that vlincRNAs represent a
global property of the human genome, and advances the
theory that such RNAs mediate the functions of variants
uncovered by GWAS (also see below).
Emerging patterns of lncRNA function in disease
A number of recent examples indicate that ncRNAs can
underlie the function of non-coding GWAS SNPs. Per-
haps the best-studied example is ANRIL, a lncRNA
transcribed from the 9p21.3 locus. the single greatest
GWAS risk factor for atherosclerosis that is currently
known [35]. Remarkably, the expression level of this
ncRNA stands out as the variable most strongly associated
with the disease phenotypes linked to 9p21.3 [35]. Recent
work has highlighted the importance of the atherogenic
SNPs in this locus by demonstrating that ANRIL functions
by trans-regulating over 900 genes [36]. The study com-
bined various in vitro experiments with measurement of
gene expression in 2,280 patients with cardiovascular dis-
ease from the Leipzig Heart Study to show that these
ANRIL-regulated genes can be classified into known
atherogenic Gene Ontology terms such as ‘cell adhesion’
and ‘apoptosis’ [36].The study further showed that ANRIL interacts with
the PRC2 chromatin signaling complex, and requires an
intact Alu sequence (a short repeated sequence present
in thousands of copies in the human genome) for its
regulatory effects [36]. Delivery of the PRC2 complex,
which promotes H3K27 trimethylation and repression
of gene expression, to its targets via the Alu-mediated
interaction thus provides an attractive model for ANRIL
function. Other systems have previously provided similar
examples of Alu repeats mediating intermolecular interac-
tions between RNA molecules, and leading to functional
consequences [37,38]. All this evidence suggests that
many other lncRNAs might function through intermo-
lecular interactions mediated by Alu and other abundant
repeated sequences in mammalian genomes.
The molecular mechanism of ANRIL function illustrates
a potential general paradigm in gene expression regulation
that promises to explain the function of large numbers of
lncRNAs. In this model, one type of RNA species could
regulate hundreds of targets in trans via intermolecular
interactions, a mode of regulation previously associated
primarily with short RNAs such as micro RNAs. How-
ever, it is becoming increasingly clear that lncRNAs can
function in this manner, perhaps by providing scaffolds
that bring together various protein and RNA molecules
[39]. In this regard, the functions of ANRIL parallel
those of the lincRNA HOTAIR, which also trans-regulates
hundreds of genes by changing the chromatin occupancy
of PRC2 [40].
A newly discovered vlincRNA associated with Hemolysis,
elevated liver enzymes, low platelet count syndrome pro-
vides another prominent example of this mode of function
[41]. While this syndrome represents a mendelian disorder,
mapped using a traditional genetic analysis of affected
families, the mutations occur in a non-coding region
that harbors an ncRNA approximately 200 kb long.
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stability of this RNA [41], which also functions by trans-
regulating hundreds of target genes.
Impressive as the aforementioned examples are, even
more striking is the trend that has emerged from these
and other investigations: more detailed examination of
non-coding GWAS loci have increasingly led to the dis-
covery of disease-relevant transcripts in the highlighted
region. For example, a careful examination of the GWAS
region at 5p14.1 that is implicated in autism led to the
discovery of non-coding RNA antisense to a moesin
pseudogene. Further experiments determined that this
natural antisense RNA probably works in trans by lower-
ing the level of moesin protein encoded by a gene on the
X chromosome [42]. Supporting this emerging trend, de-
pletion (small interfering RNA or antisense RNA) or over-
expression of lncRNAs, even the ultra-long vlincRNAs,
now routinely results in apparent phenotypes [31,41]. The
growing wealth of examples precludes us from going into
details of the studies or even citing all of them. Suffice to
say that such functional analysis has begun to connect
ncNAs, including those transcribed from GWAS loci,
with processes such as cancer, heart disease, degenerative
diseases, and senescence [31,36,40,41,43-45].
A complex transcriptome for complex diseases
The magnitude of functional transcripts in non-coding
genomic space, many of which still remain either hidden
or under-appreciated as functional RNAs, makes it almost
certain that these RNAs will explain an important fraction
of the non-coding GWAS hits. If so, then further intriguing
questions arise. Why are mendelian disorders mostly
explained by mutations affecting protein-coding exons,
yet complex diseases are explained by mutations in
ncRNAs? Does this notion form a pattern consistent with
prevailingmechanistic models of how ncRNAs function?
Does this pattern tell us something about the underlying
systems biology of human cells?
The evidence thus far suggests positive answers to
these questions. As described above in the few examples
that have been worked out in detail, lncRNAs can act as
trans regulators, potentially master regulators, of large
numbers of known genes. Examples such as ANRIL,
HOTAIR, lincRNA-p21, and HELLP highlight this emer-
ging paradigm. A similar model of regulation occurs with
transcription factors; however, a mutation in a long ncRNA
would generally not have quite the same effect as a muta-
tion in a protein. Considering that the former usually
results in a much more flexible phenotype than the latter,
a mutation would affect rather than abrogate the inter-
action affinity of the lncRNA with its partner molecules,
such as proteins or other nucleic acids. Moreover, these
interactions occur in the context of hundreds or thousands
of competing and cooperative interactions with otherlncRNAs in a complex ecosystem that controls signaling
in the nucleus. The expected result would include small
but cooperative and cumulative effects on a large number
of downstream targets, thus displaying itself as a relatively
subtle contribution to one or possibly many complex
phenotypes.
Conclusions
Clearly, we are still at the early stages of understanding
the full complexity of functional elements encoded in
the human genome. However, recent results paint an
emerging picture of a very complex regulatory network
composed of numerous ncRNAs and their targets. Each
ncRNA molecule in this network could potentially regu-
late hundreds of other RNAs in trans. GWAS variants
could function by affecting this overarching layer of
ncRNA regulation. In fact, the recent examples of this
type of network regulation probably represent the tip of
the iceberg of its true significance in complex diseases.
Therefore, the time is right to bring the two fields together
to fully unravel the underlying relationships.
In addition, the theme of ncRNA in disease brings
with it an immediate implication for clinical research. If
ncRNAs are as intricately involved in underlying disease
mechanisms, as the data reviewed here suggest, then
clinical transcriptome sequencing (including ncRNAs)
has to come to the forefront of biomedical research.
Indeed, first indications suggest that ncRNAs represent
excellent biomarkers for cancer diagnostics [46,47]. Con-
sidering the much larger complexity of ncRNAs compared
with coding RNAs, the former represent a gigantic un-
tapped potential for clinically relevant biomarkers, in
addition to expanding our basic knowledge of molecular
events leading to disease.
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